Ventana Biotech Inc. announced that it has signed a deal with GTMC, for the distribution of Ventana's appetite suppressant and stress reducing chewing gums. The deal will see Ventana's products distributed initially to South Korea and, later, to Japan through GTMC's network of manufacturing and distribution partners. Under the terms of the deal, GTMC will negotiate agreements whereby GTMC will cover the initial costs and, thereafter, manufacturing and distribution costs will be paid through revenue share agreements. This arrangement enables Ventana to participate in the lucrative alternative biotech market without having to provide any of the upfront costs. In South Korea alone, the import of medical products has risen approximately 30% per year for the past 5 years. South Korea is among the top 15 economies in the world and its population expects a high level of medical care and choice of products. Medicated chewing gum is on the rise in South Korea and this agreement positions Ventana to be a leading supplier in an estimated billion dollar market in 2010. Ventana's first shipments are expected to be distributed in South Korea no later than the second quarter of 2010.

Ventana Biotech Inc. announced it has signed is in collaboration negotiations with PE Consortium Ltd, a company that focuses on the research and development and outsourcing of new obesity treating drug targets. The two companies have signed a Letter of Intent with a view to sign a collaboration agreement. The two companies have formalized their desire to collaborate in a recent Letter of Intent, and are presently preparing the contractual details of their collaboration. They plan to primarily focus on the sourcing of obesity treatments, but are open to future expansion to other therapeutic areas as well. PE Consortium Ltd.'s strength lies in identifying and acquiring promising obesity treatments through the relationships it has built with academic research institutions around the world, their expertise and experience in that area would be a welcome enhancement to Ventana's current sourcing efforts.

Ventana Biotech Inc. announced that it is conducting research in developing a Stress Suppressing Chewing Gum that builds on its experience with its current line of anti-obesity products. Having gained experience with stimulating the body's own natural hormones in suppressing appetite, Ventana has commenced similar research with the aim of suppressing stress.